A phase II study with mitoxantrone has been carried out in 30 metastatic breast cancer patients. Of 26 evaluable patients 7 (26.9\%) experienced a partial response; 7 (26.9\%) patients had stable disease and 12 (46.1\%) had progression. Major toxicity observed was: nausea and vomiting in 52\% of patients, moderate hair loss in 53\% of patients and leukopenia in 53\%.
A phase II study of mitoxantrone in advanced breast cancer / P., Pronzato; A., Ardizzoni; Conte, Pierfranco; M., Gulisano; R., Lionetto; L., Repetto; V., Scornavacche; M. R., Sertoli; R., Rosso. - In: CHEMIOTERAPIA. - ISSN 0392-906X. - STAMPA. - 5:(1986), pp. 150-153.
A phase II study of mitoxantrone in advanced breast cancer.
CONTE, Pierfranco;
1986
Abstract
A phase II study with mitoxantrone has been carried out in 30 metastatic breast cancer patients. Of 26 evaluable patients 7 (26.9\%) experienced a partial response; 7 (26.9\%) patients had stable disease and 12 (46.1\%) had progression. Major toxicity observed was: nausea and vomiting in 52\% of patients, moderate hair loss in 53\% of patients and leukopenia in 53\%.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
